Your browser does not support JavaScript!

Home    Στοχευμένες θεραπείες στο λέμφωμα Hodgkin  

Results - Details

Add to Basket
[Add to Basket]
Identifier 000441438
Title Στοχευμένες θεραπείες στο λέμφωμα Hodgkin
Alternative Title Target therapy for Hodgkin lymphoma
Author Βιολάκη, Βασιλική
Thesis advisor Ποντίκογλου, Χαράλαμπος
Reviewer Παπαδάκη, Ελένη
Στειακάκη, Ευτυχία
Abstract Hodgkin ՚s lymphoma is one of the first cancers to be rendered curable by combination chemotherapy. Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) is considered as the standard of care for most patients as it offers an excellent balance of efficacy and toxicity. However, though the majority of patients can be cured with ABVD or alternative regimens (ΒΕΑCOPP esc.) even in advanced stages, recurrent, and refractory disease remains a significant problem. Additionally, long term toxicity is becoming a major issue, as survivors cured of Hodgkin’s lymphoma outnumber the patients with active disease. Advances in our understanding of the pathobiology of the disease culminated in the development of novel targeted therapies, many of which have demonstrated remarkable activity in the relapsed/refractory setting and are currently investigated as frontline treatment. The major advance in the therapy of Hodgkin՚s lymphoma is the development of anti-CD30, Brentuximab vedotin and PD-1 inhibitors, Nivolumab/Pembrolizumab for the treatment of relapse/refractory HL.
Language Greek
Subject Immunotherapy
Ανοσοθεραπεία
Issue date 2021-07-29
Collection   School/Department--School of Medicine--Department of Medicine--Post-graduate theses
  Type of Work--Post-graduate theses
Views 1344

Digital Documents
No preview available

Download document
View document
Views : 20